Latest TECH news

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

PRNewsWire · Wed, 23 Sep 2026 09:20:00 -0400

MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "Merger Agreement") at a Special Meeting of Shareholders held today.

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

PRNewsWire · Tue, 22 Sep 2026 09:00:00 -0400

New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across the DACH and broader EMEA regions Center strengthens collaboration, training and innovation within Europe's life sciences community MINNEAPOLIS and DÜSSELDORF, Germany, Sept. 22, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise.

Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?

Zacks Investment Research · Fri, 11 Sep 2026 12:31:03 -0400

Techne (TECH) reported earnings 30 days ago. What's next for the stock?

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

GlobeNewsWire · Wed, 09 Sep 2026 11:43:00 -0400

BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals

PRNewsWire · Tue, 01 Sep 2026 06:30:00 -0400

Fiscal 2026 highlights: Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the company's electricity consumption now comes from renewable sources First comprehensive Scope 3 emissions inventory completed MINNEAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

GlobeNewsWire · Mon, 24 Aug 2026 13:56:00 -0400

BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders

Business Wire · Sat, 22 Aug 2026 04:43:00 -0400

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Bio-Techne and its board of directors violat.

Market information is provided for research and visualization and is not investment advice.